drugset
drugset / Trial / NCT04644198

Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica

NCT04644198 ↗

Phase 2 Unknown 30 enrolled The University of The West Indies
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection. The investigators propose to test whether the use of Convalescent plasma given to patients with severe COVID-19 disease will decrease risk of death, decrease use of ventilatory support decrease biomarkers of inflammation and improve measures of viral replication compared with controls subjects who were not transfused.Convalescent plasma, will be collected from persons who are more than 21 days post negative viral testing or 28 days post resolution of symptoms.

Timeline

Start
2021-06-01
Primary completion
2021-12-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Convalescent Plasma Infusion Unknown 250 ml —

Indications

No indication recorded.